David Thomas
Omico; UNSW Sydney · Peter MacCallum Cancer Centre, Australia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Thomas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06003621 · Tiragolumab and Atezolizumab in Advanced Pan-cancer PatientsOmico · active not recruiting · Solid Tumor, Adult · principal investigator
- Ph1/Ph2NCT00753727 · Sunitinib and Radiation in Patients With Resectable Soft-tissue SarcomaAustralasian Sarcoma Study Group · unknown · Soft Tissue Sarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 74 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:17 UTC. The ranking covers the 200 most relevant of 523 PubMed records, and a shared surname and initials can bring in a namesake. All 523 on PubMed
- Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.N Engl J Med · 20061,039 citationsRCR 20.7
- 674 citationsRCR 12.7
- Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.Lancet Oncol · 2010527 citationsRCR 14.8
- 512 citationsRCR 10.7
- Rituximab dose-escalation trial in chronic lymphocytic leukemia.J Clin Oncol · 2001479 citationsRCR 10.3
- Randomized trial of breast self-examination in Shanghai: final results.J Natl Cancer Inst · 2002454 citationsRCR 12.5
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.Lancet · 2019400 citationsRCR 13.4
- 399 citationsRCR 8.3
- 398 citationsRCR 20.0
- 374 citationsRCR 20.7